报告COVID-19疫苗试验中的健康公平考虑:一个方法论性审查
Roger Kou1, Sarah Lopes Sadafi2, Rachael Principato3
1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
COVID-19疫苗试验很少报告健康公平分层者的结果,限制了对差异的理解. 使用像PROGRESS-Plus这样的框架来改善报告对公平的公共卫生至关重要.
科学领域:
- 公共卫生 公共卫生
- 临床试验方法论 临床试验方法论
- 健康 公平 研究 健康 公平 研究
背景情况:
- 针对COVID-19疫苗的随机对照试验 (RCT) 构成了公共卫生决策的证据基础.
- 建议卫生公平分层机构报告试验结果,以减少偏见和研究差距.
- 在COVID-19疫苗试验中使用健康公平分层的程度仍然未经检查.
研究的目的:
- 在已发表的COVID-19疫苗RCT中批判性地检查卫生公平分层的利用情况.
- 根据PROGRESS-Plus框架评估健康公平报告的全面性.
主要方法:
- 在2023年2月8日之前,对144份COVID-19疫苗试验手稿进行了方法审查.
- 基于PROGRESS-Plus框架的评估,包括12个健康公平分层.
- 参与者描述的评估,与股权相关的结果报告和影响的讨论.
主要成果:
- 年龄,居住地和性别/性别经常被用来描述参与者;种族/种族在64%的试验中被使用.
- 年龄最常用于结果分类 (67%),其次是性别/性别 (35%).
- 没有报告关于宗教,社会经济地位,性取向或关系特征的试验;只有47%的人满足了所有三个报告标准.
结论:
- COVID-19疫苗试验表明,健康公平分层的使用有限,结果不经常分类或讨论后果.
- 使用PROGRESS-Plus等框架进行增强的报告对于对健康差异的细微了解至关重要.
- 改进的报告将更好地告知公共卫生行动,以解决疫情加剧的健康不平等问题.
更多相关视频
14:32Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care
Published on: February 16, 2011
09:33Visualizing Field Data Collection Procedures of Exposure and Biomarker Assessments for the Household Air Pollution Intervention Network Trial in India
Published on: December 23, 2022
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
Bias in Epidemiological Studies
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Principles of Disease Surveillance
